|
Caprion Pharmaceuticals Announces New Biomarker Discovery Collaboration with Vertex Pharmaceuticals |
|
|
|
30 Mar 2006 |
MONTREAL, Canada | Mar 29, 2006 | Caprion Pharmaceuticals Inc.'s Applied BioMedicine group today announced a research collaboration with Vertex Pharmaceuticals Incorporated. The collaboration will use Caprion's CellCarta® proteomics platform to support clinical biomarker discovery. Caprion will identify potential pharmacodynamic biomarkers in samples from certain clinical and pre-clinical studies conducted by Vertex.
"Caprion is looking forward to working with Vertex on this clinical biomarker discovery collaboration," noted Dr. Daniel Chelsky, Chief Scientific Officer at Caprion. "We believe that Caprion's capabilities in the discovery of protein biomarkers may significantly impact development efforts for one or more Vertex compounds."
Caprion's proprietary proteomics platform comprehensively profiles proteins and provides an unprecedented level of protein expression and identification in tissues and blood plasma. Caprion is presently conducting biomarker discovery programs in other indications for several pharmaceutical and biotechnology companies and its own clinical programs.
About Caprion Pharmaceuticals Inc.
Caprion Pharmaceuticals Inc. is a clinical-stage biotechnology company developing a pipeline of drug candidates in oncology and infectious diseases and applying its leading and proprietary proteomics technologies to enable the discovery and development of novel pharmaceutical products. Caprion has two programs in clinical development: ShigamAbsTM, monoclonal antibodies targeting E. coli-produced Shiga Toxins, is expected to enter Phase II/III clinical trials for E. coli infection by the fourth quarter of 2006. CAP-232, a peptide with broad applicability in several oncology indications, is scheduled to enter two Phase IIb clinical studies by the fourth quarter of 2006.
Caprion's proteomics discovery platform - CellCarta® - is the leading means for profiling proteins in solid tissues and plasma. CellCarta® is a proprietary, state-of-the-art proteomics technology platform that serves as an engine for unparalleled disease target identification, predictive medicine and the creation of a proprietary therapeutic product pipeline. The power of Caprion's technology has been successfully leveraged to secure multiple, platform-validating, revenue generating partnerships surrounding oncology target identification and clinical biomarker discovery. Collaborations with major bio-pharmaceutical partners – including Biogen Idec, Abbott, ICOS, Wyeth and Boehringer Ingelheim, among others – have generated over US$30 million in revenues, more than US$100 million in potential future milestone payments and the additional potential for significant future royalties on drugs developed by its partners.
For more on Caprion, please visit www.caprion.com.
FOR MORE INFORMATION CONTACT:
Caprion Pharmaceuticals
Nathalie Uson
Caprion Pharmaceuticals Inc.
(514) 940-3617
SOURCE: Caprion Pharmaceuticals Inc. |
